The case for testing Pfizer's Paxlovid for treating long COVID

The case for testing Pfizer’s Paxlovid for treating long COVID

Two long COVID patients recover after Paxlovid treatment Side effects, safety issues need to be studied CHICAGO, April 18 (Reuters) – Reports of two patients who found relief from long COVID after taking Pfizer Inc’s (PFE.N) antiviral Paxlovid, including a researcher who tested it on herself, provide intriguing evidence for clinical trials to help those …

The case for testing Pfizer’s Paxlovid for treating long COVID Read More »